You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

December 28, 2017

Laos: Requirements for Businesses Importing and Exporting Medicines and Medical Products/Devices

The Ministry of Health in Laos has issued a Decision on the Establishment of Businesses for the Import and Export of Medicine and Medical Products No. 1820/MoH dated August 25, 2017 (the Decision), to provide information on setting up and conducting businesses related to the import and export, distribution, wholesale, and manufacture of medicines and medical products/devices.

The Decision aims to address issues that the Law on Medicine and Medical Products No.07/NA dated December 21, 2011, failed to address, and it also stipulates the requirements necessary to establish a medicine or medical products company, and subsequent requirements needed for the company when it starts to conduct its activities.

Scope of Activities Addressed by the Decision

In Laos, laws alone often do not provide complete information on the criteria necessary to set up or conduct a business. This is also the case for the Law on Medicine and Medical Products, which provides broad principles on the management of medicine and medical products/devices in terms of registration, standard requirements, advertisements of these products, and general prohibitions for operators during their business operations.

Therefore, the Decision perpetuates the long-standing Lao practice of using regulations to complete the law and provide details on the steps and requirements necessary to register and conduct contemplated activities in Laos.

The Decision provides requirements for the establishment and operations of businesses contemplating import and export of medicine and medical products/devices, and distribution and domestic wholesale activities for these products. Provisions in the Decision also cover factories involved in the manufacturing of medicines and medical products/devices, as well as requirements for places to be used to store goods and the minimum maintenance and warehousing standards and requirements for such goods.

Requirements to Establish a Legal Entity

The Decision clarifies that both local and foreign business investors can obtain a license to conduct businesses related to the import and export, distribution, wholesale, and manufacture of medicines and medical products/devices. This clarification, however, still sets out a number of general restrictions on foreign investors.

The Decision sets out that an applicant for business registration should have at least one pharmacist who has received appropriate education in Laos or abroad, and who has been approved by the Ministry of Health to conduct such activity. Pharmacists who are employed by companies that import and export medicine and medical products should have at least five years of experience, while branches or wholesale companies require either a pharmacist, or a pharmacist assistant, who has at least four years of experience.

A company registration applicant should not currently be under investigation or charges, or subjected to sanctions related to the sale of drugs or narcotics. Furthermore, applicants must have good physical and mental health. The Law on Medicine and Medical Products further requires: (1) good ethics for medicine and business; (2) personnel with knowledge and capabilities; (3) measures relating to safety and environmental practices; and (4) appropriate premises, necessary facilities, and standardized warehouses and transport vehicles.

It is important to note that both the Law on Medicine and Medical Products and the Decision do not directly address registered capital, and they leave specific issues or requirements to other laws and regulations to address. Minimum registered capital requirements are thus addressed in the Decision of the Ministry of Industry and Commerce on Wholesale and Retail Businesses No. 1005/MOIC dated May 22, 2015, which states that the Lao regulatory framework allows a foreign investor to wholly own an import-export, distribution, or wholesale-related activity, with the registered capital requirements for the activities dependent on the share ratio that a foreign investor holds in the company, as follows:

  • A company with foreign ownership of 50% or less has registered capital requirements of LAK 4 billion (approximately USD 480,000) to LAK 10 billion (approximately USD 1.2 million).
  • A company with foreign ownership of 70% or less has registered capital requirements of LAK 10 billion to LAK 20 billion (approximately USD 2.4 million).
  • A company with foreign ownership of 100% has registered capital requirements of LAK 20 billion or more.

The Decision also seeks to regulate the organizational structure of a company, as it imposes bodies or departments that are not mandatory for companies per se. Accordingly, a company must have an internal organization chart that includes at least a director and a board of directors (which therefore implies that a director, and second director or a deputy director, may be necessary), along with the following departments: (1) financial accounting; (2) warehouse accounting; (3) pharmacy; (4) technical committee; and (5) other departments, as required.

Registration Process

The Decision provides a list of documents that must be submitted for a new application to be considered by relevant authorities, and also for a renewal application for a granted license.

The registration of businesses related to the import and export, distribution, wholesale, and manufacture of medicines and medical products/devices is divided into two steps. First, approval must be obtained from the Ministry of Industry and Commerce or its related departments, which are in charge of general business registration. Once approval is obtained, the application is passed to the health sector in the vicinity where the business will be established, either at the city, provincial, or Capital Health Office level. The application is then passed to the Department of Food and Drugs for their opinion, before it is submitted to the Minister of Health, who will issue an operating license.

According to the Decision, once the application has reached the health sector stage, consideration of the dossier should take no more than 90 days. In case of a license renewal, the Food and Drug Department will be responsible for approving the renewal. Once issued, an operating license is valid for a period of two years, and subsequent renewals must be undertaken three months before its expiry date.

Post-Establishment Requirements

The Decision also provides other requirements that need to be fulfilled after a legal entity is established, which range from the storage of documents on the company’s premises, to setting up systems to ensure the safety of medicine and medical products/devices which will be handled by the business operators. Accordingly, such operators should retain the following documents on their company premises:

  • Standards for Operation Procedure in relation to tasks which are to be performed by the company, branch, and agent;
  • All relevant laws, regulations, and notifications in respect of drugs and medical products;
  • Guidelines on the utilization of drugs;
  • Monitoring booklets that substantiate the inspections of drugs and medical products performed by government inspectors;
  • Records of the medicine and medical products/devices that have undergone the registration process/notification and that have already been approved by the relevant authorities;
  • A list of the names of suppliers, along with their address, responsible contact person, and contracts detailing the business relationship with the operator;
  • Monitoring list for medicine and products in the company/branch, such as: (1) products purchased; (2) products distributed; (3) actual outstanding stock with expiration date; (4) their lot numbers; and (5) the source of supply;
  • Adverse drug reaction report forms;
  • Copies of bills/invoices related to purchased imported and exported goods of the company/branch. Such bills/invoices must provide information required under laws/regulations on medicine and medical products/devices. These documents must be maintained for at least five years;
  • Copies of the complete documents pertaining to the import, export, and transportation of medicine and medical products. These documents must be maintained at the companies and its branches for at least five years;
  • A report, which must be produced every six months, detailing the activities of the company, and a list that tracks the importation and distribution of products; and
  • A list of drugs that require special management, such as narcotic and psychotropic drugs, and other lists, as required.

In addition to documentation requirements, certain obligations may also be imposed on specific operators, depending on their activities and responsibilities.

Companies that import or export medicine and medical products/devices must have a system to track the quality of their product, monitor the effects of medicine, or provide alerts on the safety of a particular type of medicine (i.e., pharmacovigilance) that falls under the responsibility of the distributor. Moreover, companies have the responsibility to retain or recall products that are the subject of safety and quality concerns that have occurred after their distribution.

Additional requirements may be imposed in accordance with specific activities to be performed by a company. For instance, companies that also modify the bundle or container of medicine or medical products /devices must have a storage place and equipment that are specifically designed, and certified by relevant authorities, for the performance of such actions.

Warehousing and Maintenance

The Decision sets out minimum standards for warehouses where import-export companies store their medicine or medical products/devices.

An import-export warehouse must have the necessary equipment and adequate methods to maintain the storage facility, which must be included in their Good Wholesaling Practice. Likewise, good storage practices may also be required from the facility operator. If narcotic and psychotropic drugs are to be stored, these must be stored in an area that differs from the storage places used for other medicine or medical products/devices. A cold storage facility should have a temperature that ranges from two to eight degrees Celsius, and must have a thermometer or other device to ensure that medicine stays at the appropriate temperature.

If vaccines or biological products are to be stored, the management and distribution standards of these products, the warehouse used to store them, and the vehicles used to transport them must meet requisite regional and international standards.

In the event that regulations require product packaging to be changed, the company must have proper equipment and packaging procedures, which are approved by relevant authorities to ensure they are of good quality.

Distributors and wholesalers will also have specific requirements in regard to warehouses where medicine and medical products are stored, which will differ slightly from storage facilities used by import-export companies in regard to the size of the storage unit, the criteria for determining good storage practice, and the transportation requirements for such products.

Conclusion

The Decision was not only enacted to fill the void and address issues that the Law on Medicine and Medical Products did not address, but it also reiterates the commitment of Lao authorities to implement and impose standards that meet regional and international requirements, which are also reflected in broader legislative changes related to consumer protection being implemented in Laos, including a May 2017 decision on the management of packaged products.

The strong intention of Laos to meet regional standards for the transit of goods, including medicine and medical products, coupled with its geographically strategic location between many ASEAN countries and China, could help the country emerge as a key transportation hub in the region in the near future.

RELATED INSIGHTS​ 

October 15, 2025
The Indonesian Food and Drug Administration (BPOM) has introduced more stringent oversight of health supplements containing probiotics with new guidelines that require clinical trials for certain products and expanded documentation standards. BPOM Regulation No. 17 of 2025 replaces the previous 2021 regulation and establishes a comprehensive framework for evaluating probiotic strains used in health supplements. Assessment Requirements The new regulation expands the scope of assessment to include not only categorization and documentation but also technical procedures, strain classification, and clinical trial requirements. Unlike the previous regulation, which provided general guidance, the updated framework creates a comprehensive system for evaluating both registered probiotic strains and new or combined strains. Manufacturers must now submit supporting documentation covering strain identification and functional characterization, safety, efficacy, and product quality. The previous regulation required documentation only on safety, efficacy, and quality. Clinical Trials One of the most significant changes is the requirement for clinical trials conducted in Indonesia for applications that include benefit claims other than maintaining digestive health, or where there are modifications to benefit claims. The regulation specifies that phase 1 trials must demonstrate safety, while phase 2 trials must validate efficacy using statistically valid methods such as double-blind, randomized, placebo-controlled studies). In addition, phase 3 and phase 4 trials may be required, and postmarket surveillance data must be submitted. Technical Assessment Framework Annex 4, a newly introduced section, establishes technical procedures for assessing health supplements containing probiotics in Indonesia. This comprehensive framework outlines criteria for evaluating new probiotic strains, including strain identification, functional characterization, safety, efficacy, and product quality. The annex introduces a clear classification of claims for health supplement products containing probiotics: General claims(e.g., maintaining digestive health). Functional claims(e.g., normal biological function or activity in the body). Risk reduction claims(e.g., lowering disease risk). The regulation restricts use of the term
October 3, 2025
On September 26, 2025, the Contract Committee under Thailand’s Consumer Protection Board issued a regulation that aims to standardize contracts and enhance consumer protection within the beauty and wellness industry. The Notification on Prescribing the Beauty Service Business as a Contract-Controlled Business B.E. 2568 (2025), which takes effect on January 24, 2026, requires business operators to use a prescribed standard contract in Thai and adhere to strict mandatory provisions and prohibitions. These regulations apply to operators across all in-person and online service channels, including via digital platforms. “Beauty services business” is defined as the provision of services under an agreement allowing consumers to receive a series of treatments, either over a set number of sessions or within a set period. This includes massage, spa, other methods for cleanliness, beauty, or care of facial or body skin, and weight control and body shaping—including services offered electronically. The law excludes surgery, liposuction, and medical treatments performed by licensed practitioners. The notification establishes the following key requirements: Mandatory contract and formatting. All contracts with consumers must use the standard contract form, in Thai, with clear, readable text (minimum font size of 2 millimeters, no more than 11 characters per inch), and include all essential terms from the annexed form. Contract execution. Contracts must be made in duplicate, with one copy given to the consumer at signing. For agreements concluded through electronic channels, the process must comply with the Electronic Transactions Act and use the same required terms. Digital platforms. Business operators who provide services facilitated through a digital platform as an intermediary are ultimately responsible for ensuring the consumer receives a compliant contract. Prohibited clauses. The law prohibits clauses that limit or exclude liability for damages to life, body, health, mind, or property resulting from breach of contract or a wrongful act;
September 16, 2025
Since Thailand formally removed Mitragyna speciosa (kratom) from the list of narcotic drugs, the country has progressed from outright prohibition to a structured, license-based regime. While the Ministry of Public Health oversees cannabis plant regulation, the Ministry of Justice (MOJ) is the regulatory authority overseeing kratom plants. For the avoidance of doubt, separate Ministry of Public Health notifications prohibit the use of kratom as a food ingredient unless a food safety evaluation has been conducted; however, this restriction does not affect trade in unprocessed leaves per se. For businesses in Thailand dealing exclusively in kratom leaves, the most consequential development is the Ministerial Regulation on the Application for Permits and Notifications for the Importation and Exportation of Kratom Leaves B.E. 2568 (2025), a bylaw of the Kratom Plant Act 2022. The ministerial regulation establishes the following notable definitions: “Kratom leaves”: Fresh or dried leaves in their natural, unprocessed state (no extracts, concentrates, or infused products). “Import/Export”: Any act of bringing kratom leaves into or out of Thailand, whether for commercial sale, industrial processing abroad, or research. Import/Export Licensing Under the Kratom Plant Act, a license is mandatory for importing or exporting kratom leaves. Individuals, juristic persons, community enterprises, and state agencies in Thailand are eligible to obtain a license to import (or a license to export) kratom leaves. Licenses are available to qualified individuals and juristic persons. Individuals must satisfy the following qualifications to be eligible for a license: Thai nationality, ≥ 20 years old, resident in Thailand. Not incompetent, quasi-incompetent, or under legal guardianship. No license suspension currently in force under the Kratom Act or Narcotics Code. No license revocation in the previous two years. No conviction under the Kratom Act or Narcotics Code within the previous two years (unless fully released from punishment). Juristic persons must satisfy
September 4, 2025
With advancements in health technology, telemedicine has taken on a wider online presence in Thailand. Under the Medical Facility Act, licensed clinics and hospitals may now diagnose, prescribe, and issue electronic prescriptions during a video call, provided they maintain patient confidentiality and proper recordkeeping. As a complementary concept, a telepharmacy allows a pharmacist to verify prescriptions, counsel patients, and dispense medication from a remote site. Hospitals, clinic chains, and some retail pharmacy groups have adopted “drive-thru” or “locker” pick-up points where drugs are bagged only after a real-time video consultation with a registered pharmacist. The clear benefits of telehealth include shorter waiting times and broader access to specialists, which is in the public interest. Drug Distribution and Advertising in Thailand The online pharmacy ecosystem creates a legal bridge in that once a teleconsulting doctor issues an e-prescription, a licensed pharmacy can lawfully dispense and deliver the medicine prescribed to the patient’s door. Nonetheless, the critical compliance component remains the advertising of medicinal drugs. It is still not allowed to advertise prescription/pharmacy-dispensed drugs to the public in Thailand. Although Thailand’s Drug Act of 1967 was written more than half a century ago, it still governs the trading of every medicinal drug that makes its way to consumers in Thailand—whether bought at a pharmacy or delivered with a few taps on a smartphone. First and foremost, the pharmacy must hold a license to sell medicinal drugs as a retailer. It is also mandatory that arrangements be made for a pharmacist to be on duty during opening hours. Drugs are classified into three main categories: prescription drugs, pharmacy-dispensed drugs, and over-the-counter (OTC) drugs. The listing of OTC drugs with their prices via an online platform is allowed, as only OTC drugs may be advertised directly to the public. However, naming or showing